Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for AUROPHARMA.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for AUROPHARMA.BO and 80,000+ other tickers.
See exactly how AUROPHARMA.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for AUROPHARMA.BO and 80,000+ other tickers.
Aurobindo Pharma Limited is a global pharmaceutical company specializing in the production of generic formulations and active pharmaceutical ingredients (APIs). Its operations span across India, the United States, Europe, and other international markets. The company's product portfolio includes a diverse range of finished dosage forms, such as oral medications, injectable drugs, and over-the-counter (OTC) remedies. Concurrently, it supplies APIs crucial for various therapeutic areas, supporting the development of products in biosimilars, dermatology, respiratory care, vaccines, peptides…
No recent news available.